Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Verastem (VSTM) Long-Term Debt Issuances (2017 - 2025)

Verastem's quarterly Long-Term Debt Issuances came in at $75.0 million in Q1 2025, up 402.75% quarter-over-quarter from $14.9 million in Q1 2023.

Verastem has reported Long-Term Debt Issuances for 6 years, with the latest figure at $75.0 million in Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Issuances changed N/A year-over-year to $75.0 million; the trailing twelve-month figure through Dec 2025 stood at $75.0 million (changed N/A YoY), and the FY2025 full-year result was $75.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q1 2025 stood at $75.0 million, up from $14.9 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $75.0 million in Q1 2025, with the low at -$624000.0 in Q2 2022.
  • Average Long-Term Debt Issuances over 3 years is $28.5 million, with a median of $19.8 million recorded in 2022.
  • Peak annual rise in Long-Term Debt Issuances reached 39.78% in 2023, while the deepest fall reached 39.78% in 2023.
  • Tracing VSTM's Long-Term Debt Issuances over 3 years: stood at -$624000.0 in 2022, then soared by 2490.71% to $14.9 million in 2023, then jumped by 402.75% to $75.0 million in 2025.
  • The last three Long-Term Debt Issuances figures came in at $75.0 million (Q1 2025), $14.9 million (Q1 2023), and -$624000.0 (Q2 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 2.73 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Verastem 425.60 Mn 243.93 Mn 15.90 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 75.00 Mn
Mar 31, 2025 75.00 Mn
Mar 31, 2023 14.92 Mn
Mar 31, 2023 14.92 Mn
Jun 30, 2022 -624,000.00
Jun 30, 2022 -624,000.00
Mar 31, 2022 24.77 Mn
Mar 31, 2022 24.77 Mn
Dec 31, 2019 -9.13 Mn
Dec 31, 2019 -9.13 Mn
Jun 30, 2019 4.69 Mn
Jun 30, 2019 4.69 Mn
Mar 31, 2019 5.00 Mn
Mar 31, 2019 5.00 Mn
Jun 30, 2018 10.00 Mn
Jun 30, 2018 10.00 Mn
Dec 31, 2017 12.43 Mn
Dec 31, 2017 12.43 Mn
Mar 31, 2017 2.39 Mn
Mar 31, 2017 2.39 Mn